|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: RNF125 |
Gene summary for RNF125 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | RNF125 | Gene ID | 54941 |
| Gene name | ring finger protein 125 | |
| Gene Alias | TNORS | |
| Cytomap | 18q12.1 | |
| Gene Type | protein-coding | GO ID | GO:0000209 | UniProtAcc | Q96EQ8 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 54941 | RNF125 | NAFLD1 | Human | Liver | NAFLD | 8.99e-04 | 5.05e-01 | -0.04 |
| 54941 | RNF125 | HCC1 | Human | Liver | HCC | 4.42e-03 | 6.21e-01 | 0.5336 |
| 54941 | RNF125 | HCC2 | Human | Liver | HCC | 3.91e-12 | 1.16e+00 | 0.5341 |
| 54941 | RNF125 | HCC5 | Human | Liver | HCC | 4.03e-13 | 1.02e+00 | 0.4932 |
| 54941 | RNF125 | S028 | Human | Liver | HCC | 4.90e-02 | 1.71e-01 | 0.2503 |
| Page: 1 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:00002095 | Liver | NAFLD | protein polyubiquitination | 51/1882 | 236/18723 | 1.04e-07 | 8.10e-06 | 51 |
| GO:00305226 | Liver | NAFLD | intracellular receptor signaling pathway | 55/1882 | 265/18723 | 1.39e-07 | 1.03e-05 | 55 |
| GO:0039535 | Liver | NAFLD | regulation of RIG-I signaling pathway | 7/1882 | 20/18723 | 2.44e-03 | 2.27e-02 | 7 |
| GO:00028313 | Liver | NAFLD | regulation of response to biotic stimulus | 49/1882 | 327/18723 | 2.94e-03 | 2.66e-02 | 49 |
| GO:0032102 | Liver | NAFLD | negative regulation of response to external stimulus | 60/1882 | 420/18723 | 3.34e-03 | 2.93e-02 | 60 |
| GO:0039529 | Liver | NAFLD | RIG-I signaling pathway | 8/1882 | 27/18723 | 3.97e-03 | 3.34e-02 | 8 |
| GO:003052222 | Liver | HCC | intracellular receptor signaling pathway | 171/7958 | 265/18723 | 3.00e-13 | 1.61e-11 | 171 |
| GO:000020921 | Liver | HCC | protein polyubiquitination | 151/7958 | 236/18723 | 1.90e-11 | 7.59e-10 | 151 |
| GO:000961511 | Liver | HCC | response to virus | 210/7958 | 367/18723 | 7.32e-09 | 1.86e-07 | 210 |
| GO:0039528 | Liver | HCC | cytoplasmic pattern recognition receptor signaling pathway in response to virus | 30/7958 | 34/18723 | 3.88e-08 | 8.39e-07 | 30 |
| GO:00027533 | Liver | HCC | cytoplasmic pattern recognition receptor signaling pathway | 46/7958 | 60/18723 | 7.37e-08 | 1.49e-06 | 46 |
| GO:00022211 | Liver | HCC | pattern recognition receptor signaling pathway | 107/7958 | 172/18723 | 1.37e-07 | 2.58e-06 | 107 |
| GO:00395291 | Liver | HCC | RIG-I signaling pathway | 24/7958 | 27/18723 | 7.23e-07 | 1.12e-05 | 24 |
| GO:00516071 | Liver | HCC | defense response to virus | 151/7958 | 265/18723 | 1.27e-06 | 1.85e-05 | 151 |
| GO:01405461 | Liver | HCC | defense response to symbiont | 151/7958 | 265/18723 | 1.27e-06 | 1.85e-05 | 151 |
| GO:00985861 | Liver | HCC | cellular response to virus | 57/7958 | 84/18723 | 2.30e-06 | 3.11e-05 | 57 |
| GO:0032479 | Liver | HCC | regulation of type I interferon production | 60/7958 | 95/18723 | 3.84e-05 | 3.80e-04 | 60 |
| GO:0032606 | Liver | HCC | type I interferon production | 60/7958 | 95/18723 | 3.84e-05 | 3.80e-04 | 60 |
| GO:0039531 | Liver | HCC | regulation of viral-induced cytoplasmic pattern recognition receptor signaling pathway | 20/7958 | 24/18723 | 4.92e-05 | 4.70e-04 | 20 |
| GO:00028321 | Liver | HCC | negative regulation of response to biotic stimulus | 66/7958 | 108/18723 | 7.24e-05 | 6.50e-04 | 66 |
| Page: 1 2 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| RNF125 | SNV | Missense_Mutation | rs201216500 | c.173G>A | p.Arg58His | p.R58H | Q96EQ8 | protein_coding | tolerated(0.84) | benign(0.134) | TCGA-EA-A5ZE-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | PD |
| RNF125 | SNV | Missense_Mutation | c.336N>T | p.Met112Ile | p.M112I | Q96EQ8 | protein_coding | tolerated(0.12) | possibly_damaging(0.838) | TCGA-EK-A3GK-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD | |
| RNF125 | SNV | Missense_Mutation | c.294G>C | p.Lys98Asn | p.K98N | Q96EQ8 | protein_coding | tolerated(0.13) | benign(0.01) | TCGA-IR-A3LH-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR | |
| RNF125 | SNV | Missense_Mutation | rs533221261 | c.590N>G | p.Thr197Ser | p.T197S | Q96EQ8 | protein_coding | tolerated(0.27) | probably_damaging(0.956) | TCGA-R2-A69V-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | SD |
| RNF125 | SNV | Missense_Mutation | novel | c.686N>G | p.Ser229Trp | p.S229W | Q96EQ8 | protein_coding | deleterious(0.01) | probably_damaging(0.996) | TCGA-AA-3930-01 | Colorectum | colon adenocarcinoma | Male | >=65 | III/IV | Chemotherapy | capecitabine | PD |
| RNF125 | SNV | Missense_Mutation | c.226C>T | p.Arg76Trp | p.R76W | Q96EQ8 | protein_coding | deleterious(0.05) | benign(0.05) | TCGA-AU-6004-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| RNF125 | SNV | Missense_Mutation | rs779498047 | c.644N>A | p.Arg215Gln | p.R215Q | Q96EQ8 | protein_coding | tolerated(0.54) | benign(0.003) | TCGA-AZ-4315-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
| RNF125 | SNV | Missense_Mutation | rs532384679 | c.158N>A | p.Gly53Asp | p.G53D | Q96EQ8 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-CM-5861-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | PD |
| RNF125 | SNV | Missense_Mutation | rs201216500 | c.173N>A | p.Arg58His | p.R58H | Q96EQ8 | protein_coding | tolerated(0.84) | benign(0.134) | TCGA-G4-6628-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
| RNF125 | SNV | Missense_Mutation | rs201216500 | c.173N>A | p.Arg58His | p.R58H | Q96EQ8 | protein_coding | tolerated(0.84) | benign(0.134) | TCGA-A5-A1OF-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 4 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |